GeneLancet, a gene editing company, owns a novel lgRNA-guided gene editing platform for developing cures for chronic HBV, HIV and monogenic diseases such as Cystic Fibrosis and Alzheimer’s disease. Guide RNA directs where CRISPR cuts. lgRNA is a single-molecule guide RNA of distinct intellectual property for CRISPR gene editors. lgRNA comprises our proprietary non-nucleotide linkers designed for efficient synthesis of modified guide RNAs and RNP conjugates for cell-targeted efficient, accurate, precise, and multiple dosing gene editing. lgRNA technology makes cost-effective and robust production of consistent high-quality single-molecule guide RNAs our routine practice. We provide CRISPR-Cas/lgRNA and its conjugates as useful gene-manipulation tools, and its high-quality arrayed libraries for genomic screenings. Visit us at: GeneLancet Biosciences, Inc. 3805 Old Easton Road, Doylestown, PA 18902 https://www.genelancetbio.com Email: info@genelancetbio.com